Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without laser for macular edema in BRVO
NCT03054766Completed
- Sponsor
- Beijing Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of ranibizumab in branch retinal vein occlusion (BRVO), sponsored by Beijing Hospital. Primary endpoint: Best Corrected Visual Acuity change at 1 year. Started Feb 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT03054766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054766.